The DOI matches its Crossref record; 40 of the 40 references it cites were found in a registry or an index.
Clonogenic assay with established human tumour xenografts
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cancer: Principles and Practice of Oncology.
(1991) · Annals of Internal Medicine · doi:10.7326/0003-4819-114-9-819_4 · Cited by 8,516
Tissue microarrays for high-throughput molecular profiling of tumor specimens
Kononen, J., Bubendorf, L., Kallionimeni, A., Bärlund, M., Schraml, P., Leighton, S., Torhorst, J., Mihatsch, M. J., Sauter, G., & Kallionimeni, O.-P. (1998) · Nature Medicine · doi:10.1038/nm0798-844 · Cited by 4,099
Carmichael, J., DeGraff, W., Gazdar, A. F., Minna, J. D., & Mitchell, J. B. (1987) · PubMed · Cited by 3,813
Primary Bioassay of Human Tumor Stem Cells
Hamburger, A. W., & Salmon, S. E. (1977) · Science · doi:10.1126/science.560061 · Cited by 1,643
Quantitation of Differential Sensitivity of Human-Tumor Stem Cells to Anticancer Drugs
Salmon, S. E., Hamburger, A. W., Soehnlen, B., Durie, B. G. M., Alberts, D. S., & Moon, T. E. (1978) · New England Journal of Medicine · doi:10.1056/nejm197806152982401 · Cited by 970
Important Advances in Oncology: 1986
Merrill, J. M. (1986) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1986.03380040106043 · Cited by 907
Important Advances in Oncology
DeVita, V. T., Hellman, S., & Rosenberg, S. A. (1991) · Anti-Cancer Drugs · doi:10.1097/00001813-199108000-00014 · Cited by 760
The National Cancer Institute: cancer drug discovery and development program.
Grever, M. R., Schepartz, S. A., & Chabner, B. A. (1992) · PubMed · Cited by 722
Gallacher, L., Murdoch, B., Wu, D. M., Karanu, F. N., Keeney, M., & Bhatia, M. (2000) · Blood · doi:10.1182/blood.v95.9.2813.009k20_2813_2820 · Cited by 322
Rapid chemosensitivity testing of human lung tumor cells using the MTT assay
Cole, S. P. C. (1986) · Cancer Chemotherapy and Pharmacology · doi:10.1007/bf00256695 · Cited by 293
Research works printed but not linked: 42
- Ferguson, 1989, Phenotypic instability of drug sensitivity in a human colon carcinoma cell line, Cancer Res., 49, 1148
- Smith, 1989, Sequential cytogenetic studies in an ovarian cancer cell line, Cancer Genet. Cytogenet., 38, 13, 10.1016/0165-4608(89)90160-X · doi:10.1016/0165-4608(89)90160-x
- Fiebig, 1987, Colony assay with human tumor xenografts, murine tumors and human bone marrow. Potential for anticancer drug development, Eur. J. Cancer Clin. Oncol., 23, 937, 10.1016/0277-5379(87)90339-7 · doi:10.1016/0277-5379(87)90339-7
- Salmon, 1984, Human tumor colony assay and chemosensitivity testing, Cancer Treat Rep., 68, 117
- Schlunk, 1980, The influence of culture conditions on the production of colony-stimulating activity by human placenta, Exp. Hematol., 8, 179
- Gallacher, 2000, Identification of novel circulating human embryonic blood stem cells, Blood, 96, 1740, 10.1182/blood.V96.5.1740 · doi:10.1182/blood.v96.5.1740
- Fiebig HH, Berger DP, Dengler WA, Wallbrecher E, Winterhalter BR. Combined in vitro/in vivo test procedure with human tumor xenografts for new drug development. In Fiebig HH, Berger DP, eds. Immunodeficient Mice in Oncology. Contrib Oncol Basel, Karger, 1992, 42, 321–351. · doi:10.1159/000421298
- Maurer, 1981, Tumor stem cell cloning in agar-containing capillaries, Naturwissenschaften, 68, 381, 10.1007/BF01058036 · doi:10.1007/bf01058036
- Hanauske, 1988, Recombinant human transforming growth factor-alpha stimulates in vitro colony formation of fresh human tumor specimens, Int. J. Cell Cloning, 6, 221, 10.1002/stem.5530060307 · doi:10.1002/stem.5530060307
- Bertelsen, 1984, Chemosensitivity testing of human solid tumors. A review of 1582 assays with 258 clinical correlations, Cancer, 53, 1240, 10.1002/1097-0142(19840315)53:6<1240::AID-CNCR2820530604>3.0.CO;2-Y · doi:10.1002/1097-0142(19840315)53:6<1240::aid-cncr2820530604>3.0.co;2-y
- Carmichael, 1987, Evaluation of a tetrazolium-based semiautomated colometric assay, Cancer Res., 47, 936
- Hoffman, 1991, Three-dimensional histoculture, Cancer Cells, 3, 86
- Inaba, 1996, In vitro-in vivo correlation in anticancer drug sensitivity test using AUC-based concentrations and collagen gel-droplet-embedded culture, Oncology, 53, 250, 10.1159/000227569 · doi:10.1159/000227569
- Sevin, 1988, Application of an ATP-bioluminescense assay in human tumor chemosensitivty testing, Gynecol. Oncol., 31, 191, 10.1016/0090-8258(88)90293-4 · doi:10.1016/0090-8258(88)90293-4
- Lieber, 1981, Anticancer drug testing in vitro, Life Sciences, 28, 287, 10.1016/0024-3205(81)90735-9 · doi:10.1016/0024-3205(81)90735-9
- Link, 1996, Regional chemotherapy directed by individual chemosensitivity testing in vitro, Clin. Cancer Res., 2, 1469
- Link, 2000, Thymidylate synthase quantitation and in vitro chemosensitivity testing predicts responses and survival of patients with isolated nonresectable liver tumors receiving hepatic arterial infusion chemotherapy, Cancer, 89, 288, 10.1002/1097-0142(20000715)89:2<288::AID-CNCR13>3.0.CO;2-O · doi:10.1002/1097-0142(20000715)89:2<288::aid-cncr13>3.0.co;2-o
- Grever, 1992, The National Cancer Institute, Semin. Oncol., 19, 622
- Shoemaker, 1985, Application of a human tumor colony-forming assay to new drug screening, Cancer Res., 45, 2145
- Berger, 1989, Quality control measures in the clonogenic assay, Proc. Am. Ass. Cancer Res., 30, 610
- Thomson, 1984, Kinetics of clonogenic melanoma cell proliferation and the limits of growth within a bilayer agar system, J. Cell. Physiol., 121, 114, 10.1002/jcp.1041210114 · doi:10.1002/jcp.1041210114
- Alley, 1982, Improved detection of drug cytotoxicity in the soft agar colony formation assay through use of a metabolizable tetrazolium salt, Life Sci., 31, 3071, 10.1016/0024-3205(82)90077-7 · doi:10.1016/0024-3205(82)90077-7
- Berger DP, Fiebig HH, Winterhalter BR. Establishment and characterization of human tumor xenograft models in nude mice. In. Fiebig HH, Berger DP, eds. Immunodeficient Mice in Oncology. Contrib Oncol Basel, Karger, 1992, 42, 23–46. · doi:10.1159/000421257
- Selby, 1983, A critical appraisal of the “human tumor stem cell assay”, N. Engl. J. Med., 308, 129, 10.1056/NEJM198301203080304 · doi:10.1056/nejm198301203080304
- Phillips RM. In vitro models of solid-tumour biology and drug delivery: Implications for and applications to target-oriented screening for novel anticancer drugs. Fiebig HH, Burger AM, eds. Relevance of Tumor Models for Anticancer Drug Development. Contrib Oncol Basel, Karger, 1999, 54, 67–80. · doi:10.1159/000425823
- Phillips, 2003, Three dimensional cellular models and hypoxia selective toxins, Onkologie, 26, 390
- Wirth, 2003, Xenograft tissue microarrays, Onkologie, 26, 388
- Kelter, 2003, A cellular high throughput screen for anticancer drug discovery, Onkologie, 26, 389
- Plowmann J, Camalier R, Alley M, Sausville E, Schepartz S. US-NCI Testing procedures. In Fiebig HH, Burger AM, eds. Relevance of Tumor Models for Anticancer Drug Development. Contrib Oncol Basel, Karger, 1999, 54, 121–135. · doi:10.1159/000425828
- Smith, 2003, 17-DMA-Geldanamycin is a novel water-soluble, orally bioavailable Hsp90 inhibitor with potent in vitro and in vivo anticancer activity, Proc. Am. Assoc. Cancer Res., 44, 153
- Smith, 2003, Modulators of heat shock protein 90 –– targeting multiple signal transduction pathways, Onkologie, 26, 386
- Jones, 1995, Randomized comparison of vinorelbine and melphalan in anthracycline-refractory advanced breast cancer, J. Clin. Oncol., 13, 2567, 10.1200/JCO.1995.13.10.2567 · doi:10.1200/jco.1995.13.10.2567
- Morris, 1998, Phase II study of vinorelbine in advanced and recurrent squamous cell carcinoma of the cervix, J. Clin. Oncol., 16, 1094, 10.1200/JCO.1998.16.3.1094 · doi:10.1200/jco.1998.16.3.1094
- Maier, 2003, Antitumor activity of CYC202, a cyclin dependent kinase inhibitor, in human tumor xenografts in vitro, Proc. Am. Assoc. Cancer Res., 44, 619
- Burger, 2001, Antitumor activity of an aqueous mistletoe extract (AME) standardized for ML-1 in human tumor cell lines and xenografts in vitro, Drug Res., 51, 748
- Sharma, 2003, Outcome of ATP-based tumor chemosensitivity assay directed chemotherapy in heavily pre-treated recurrent ovarian carcinoma, BMC Cancer, 3, 19, 10.1186/1471-2407-3-19 · doi:10.1186/1471-2407-3-19
- Bertelsen, 1983, Heterogeneity of human metastatic clones by in vitro chemosensitivity testing, Arch. Surg., 118, 1406, 10.1001/archsurg.1983.01390120036010 · doi:10.1001/archsurg.1983.01390120036010
- Kern, 1998, Heterogeneity of drug resistance in human breast and ovarian cancers, Cancer J. Sci. Am., 4, 41
- Drees, 1997, Flavopiridol (L86-8275), Clin. Cancer Res., 3, 273
- Fiebig, 1994, Cyanocyclin A and the quinocarmycin analog NSC 607097 demonstrate selectivity against melanoma xenografts in vitro and in vivo, Proc. Am. Assoc. Cancer Res., 35, 468
- Winterhalter, 1993, High antitumor activity of rhizoxin in a combined in vitro and in vivo test procedure with human tumor xenografts, Proc. Am. Assoc. Cancer Res., 34, 376
- Burger, 1999, Recombinant mistletoe lectin (rML) is a potent inhibitor of tumor cell growth in vitro and in vivo, Proc. Am. Assoc. Cancer Res., 40, 399
Cited by
Patient-Derived Xenograft Models: An Emerging Platform for Translational Cancer Research
Hidalgo, M., Amant, F., Biankin, A. V., Budinská, E., Byrne, A. T., Caldas, C., Clarke, R. B., de Jong, S., Jonkers, J., Mælandsmo, G. M., et al. (2014) · Cancer Discovery · doi:10.1158/2159-8290.cd-14-0001 · Cited by 1,742
Cell line-based platforms to evaluate the therapeutic efficacy of candidate anticancer agents
Sharma, S. V., Haber, D. A., & Settleman, J. (2010) · Nature Reviews Cancer · doi:10.1038/nrc2820 · Cited by 586
Murine Models to Evaluate Novel and Conventional Therapeutic Strategies for Cancer
Talmadge, J. E., Singh, R. K., Fidler, I. J., & Raz, A. (2007) · The American Journal of Pathology · doi:10.2353/ajpath.2007.060929 · Cited by 468
A New Model of Patient Tumor-Derived Breast Cancer Xenografts for Preclinical Assays
Marangoni, E., Vincent-Salomon, A., Auger, N., Degeorges, A., Assayag, F., de Cremoux, P., de Plater, L., Guyader, C., De Pinieux, G., Judde, J.-G., et al. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-0078 · Cited by 422
The production of 3D tumor spheroids for cancer drug discovery
Sant, S., & Johnston, P. A. (2017) · Drug Discovery Today: Technologies · doi:10.1016/j.ddtec.2017.03.002 · Cited by 404
Endogenous Purification Reveals GREB1 as a Key Estrogen Receptor Regulatory Factor
Mohammed, H., D’Santos, C., Serandour, A. A., Ali, H. R., Brown, G. D., Atkins, A., Rueda, O. M., Holmes, K. A., Theodorou, V., Robinson, J. L. L., et al. (2013) · Cell Reports · doi:10.1016/j.celrep.2013.01.010 · Cited by 400
Androgen receptor driven transcription in molecular apocrine breast cancer is mediated by FoxA1
Robinson, J. L. L., MacArthur, S., Ross‐Innes, C. S., Tilley, W. D., Neal, D. E., Mills, I. G., & Carroll, J. S. (2011) · The EMBO Journal · doi:10.1038/emboj.2011.216 · Cited by 300
50 Years of Preclinical Anticancer Drug Screening: Empirical to Target-Driven Approaches
Suggitt, M., & Bibby, M. C. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.971.11.3 · Cited by 298
Unger, C., Kramer, N., Walzl, A., Scherzer, M., Hengstschläger, M., & Dolznig, H. (2014) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2014.10.015 · Cited by 158
MASKEY, R. P., HELMKE, E., KAYSER, O., FIEBIG, H. H., MAIER, A., BUSCHE, A., & LAATSCH, H. (2004) · The Journal of Antibiotics · doi:10.7164/antibiotics.57.771 · Cited by 158
Self-citationLee, M. S., Helms, T. L., Feng, N., Gay, J., Chang, Q. E., Tian, F., Wu, J. Y., Toniatti, C., Heffernan, T. P., Powis, G., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.9153 · Cited by 123
“Primary human-tumor xenograft models were established as previously described [70].”
Mansouramycins A–D, cytotoxic isoquinolinequinones from a marine Streptomycete
Hawas, U. W., Shaaban, M., Shaaban, K. A., Speitling, M., Maier, A., Kelter, G., Fiebig, H. H., Meiners, M., Helmke, E., & Laatsch, H. (2009) · Journal of Natural Products · doi:10.1021/np900160g · Cited by 116
Self-citationSchneider, M., Huber, J., Hadaschik, B., Siegers, G. M., Fiebig, H.-H., & Schüler, J. (2012) · BMC Cancer · doi:10.1186/1471-2407-12-96 · Cited by 75
Self-citationModeling of Patient-Derived Xenografts in Colorectal Cancer
(2017) · doi:10.1158/1535-7163.mct-16-0721 · Cited by 64
Enzastaurin: A lesson in drug development
Bourhill, T., Narendran, A., & Johnston, R. N. (2017) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2017.02.003 · Cited by 55
Omoruyi, S. I., Ekpo, O. E., Semenya, D. M., Jardine, A., & Prince, S. (2020) · Apoptosis · doi:10.1007/s10495-020-01594-5 · Cited by 53
Guérin, E., Raffelsberger, W., Pencreach, E., Maier, A., Neuville, A., Schneider, A., Bachellier, P., Rohr, S., Petitprez, A., Poch, O., et al. (2012) · Molecular Medicine · doi:10.2119/molmed.2011.00120 · Cited by 44
Self-citationColombo, P.-E., du Manoir, S., Orsetti, B., Bras-Gonçalves, R., Lambros, M. B., MacKay, A., Nguyen, T.-T., Boissière, F., Pourquier, D., Bibeau, F., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.5069 · Cited by 34
Drug Development in Endometriosis and Adenomyosis: It Takes More Than Just Good Science
Groothuis, P. G., & Guo, S.-W. (2018) · Reproductive Sciences · doi:10.1177/1933719118785767 · Cited by 13
Serala, K., Bai, J., & Prince, S. (2024) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.70222 · Cited by 6
Metadata
- Authors
- Fiebig, H. H., Maier, A., & Burger, A. M.
- Venue
- European Journal of Cancer
- Publisher
- Elsevier BV
- Published
- 2004-04
- Volume
- 40
- Issue
- 6
- Pages
- 802-820
- ISSN
- 0959-8049 (ISSN-L)
- OpenAlex
- W54649336
- Cited by
- 291
- References
- 40
- FWCI
- 4.55
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.